CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions

In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:

• Optimal use of approved CAR T-cell therapies for lymphoma and ALL
• Investigational CAR T-cell therapies for multiple myeloma
• Managing CAR T-cell therapy–related toxicities

Presenters:
Michael R. Bishop, MD
Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois

Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief, Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts

Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.

Link to full program:
https://bit.ly/3iyt5zQ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.